Logo for Cereno Scientific

Cereno Scientific Investor Relations Material

Latest events

Logo for Cereno Scientific

Study Update

Cereno Scientific
Logo for Cereno Scientific

Study Update

4 Mar, 2025
Logo for Cereno Scientific

Q4 2024

25 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 12,000+ public companies

Latest reports from Cereno Scientific

Access all reports
Cereno Scientific AB (publ), a clinical stage biotech company, develops therapeutics to treat cardiovascular and rare diseases through epigenetic modulation worldwide. The company is involved in developing CER-001, which is in Phase IIa study for the treatment of acute reperfused myocardial infarction; and Phase I/II study for amyotrophic lateral sclerosis patients. It has a collaboration with Oxford BioTherapeutics Ltd. to further advance the clinical development of CER-001 for the treatment of acute myocardial infarction; and strategic alliance with Novartis to develop tissue agnostic therapeutic treatments.